Advertisement
Learn about featured clinical trials currently enrolling or search our trials database
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Disease: Pancreas
Objective: To determine the maximum tolerated dose (MTD) of OMP-59R5 when administered every other week (on Days 1 and 15) in combination with nab-paclitaxel 125 mg/m2 and gemcitabine 1000 mg/m2 on Days 1, 8 and 15 of every 28-day cycle in subjects with previously untreated stage IV pancreatic cancer (Phase 1b portion).
Disease: Solid Tumors
Objective: To assess clinical benefit associated with BKM120 treatment based on local investigator assessment. For patients with solid tumors the assessment criteria will be RECIST 1.1 and will include responses of CR or PR or SD.
Disease: Solid Tumors
Objective: To assess clinical benefit associated with MEK162 treatment based on local investigator assessment.
For patients with solid tumors the assessment criteria will be RECIST 1.1 and will include responses of CR or PR or SD.
Disease: Solid Tumors
Objective: To assess clinical benefit associated with dovitinib treatment based on local investigator assessment.
For patients with solid tumors the assessment criteria will be RECIST 1.1 and will include responses of CR or PR or SD.
Disease: Leukemia
Objective: To determine whether eltrombopag leads to early platelet recovery in older AML patients (> 60 years) who attain morphologic remission on day 14 bone marrow assessment following remission IC.
Disease: Myelodysplastic Syndrome (MDS)
Objective: Estimate Clinical Improvement rate including Complete Responses (CR), Marrow CR, Partial Responses (PR), Hematologic Improvement (HI) (CR+Marrow CR+PR+HI).
Disease: Lymphoma, Diffuse Large B Cell
Objective: To determine the safety of carfilzomib in combination with R-CHOP (CR-CHOP) in patients with newly diagnosed DLBCL and identify a recommended phase II dose (RP2D).
Disease: Multiple Myeloma
Objective: Estimate the PFS of patients treated with carfilzomib + ARRY-520 and of patients treated with single-agent carfilzomib.
Advertisement
Disease: Lymphoma
Objective: To compare the progression-free survival (PFS) as determined by an independent review facility (IRF) between the 2 treatment arms.
Disease: Multiple Myeloma
Objective: Define the tolerability and safety of MLN9708 (ixazomib) administered on a day 1,8,15 every 28 day schedule up to 4mg in combination with fixed doses of panobinostat and dexamethasone in patients with relapsed or refractory myeloma.
Disease: Breast
Objective: To evaluate the anti-cancer activity of CDX-011 in metastatic, GPNMB over-expressing, triple-negative breast cancer as measured by the objective response rate (ORR) and duration of progression-free survival (PFS).
Disease: Breast
Objective: The primary aim is to determine the value of trastuzumab given during radiation therapy (RT) compared to RT alone in preventing the subsequent occurrence of ipsilateral breast cancer recurrence, ipsilateral skin cancer recurrence, or ipsilateral DCIS (IIBCR-SCR-DCIS) in women with HER2-positive DCIS resected by lumpectomy.
Advertisement
Advertisement
Polygenic risk score could help predict who will develop this aggressive breast cancer
Platinum-eligible phase 3 trial of enfortumab vedotin and pembrolizumab yields ‘unprecedented data’
Extent of baseline burden impacts progression-free and overall survival
Further study warranted to better understand the clinical implications of these findings
Real-world study shows high response rates that are durable with commercial lisocabtagene maraleucel
Oral anticoagulants may be beneficial but need to be balanced against bleeding risks
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels